Early Surgery for Epilepsy Can Improve Outcomes for Kids
This study looked at the outcomes of surgery for children with epilepsy caused by a brain condition called focal cortical dysplasia (FCD).
-
-
EEG Abnormalities Common in Children with Language Delays
This study looked at children who have delays in language development to see how common certain brain activity patterns, called epileptiform discharges, are among them.
-
Devices & Neuromodulation | Epilepsy Research Summaries | Genetics | Imaging & EEG | New Studies | Pediatrics
MRI Abnormalities Common in Genetic Epilepsies
Researchers studied brain MRI scans of 139 children with specific genetic types of epilepsy linked to four genes: SCN1A, SCN2A, SCN3A, and SCN8A.
-
CBD Shows Promise for Reducing Seizures and Neuroinflammation
Researchers studied the effects of cannabidiol (CBD) on epilepsy, particularly focusing on its role in reducing seizures and its impact on neuroinflammation.
-
Febrile Seizures Often Recur But Don’t Increase Epilepsy Risk
This study looked at febrile seizures (FSs) in young children, specifically those aged 6 months to 3 years, who were treated at a pediatric hospital in Shanghai between April 2021 and March 2023.
-
Drug-Resistant Epilepsy | Epilepsy Research Summaries | Genetics | Imaging & EEG | New Studies | Pediatrics
New Insights on KCTD7-Related Epilepsy in Indian Children
Researchers studied six children from South India who have a rare type of epilepsy called KCTD7-related progressive myoclonic epilepsy (PME).
-
Immune Changes May Link Autism and Epilepsy in Children
Researchers studied children aged 9 to 14 years who have mild autism spectrum disorder (ASD), some of whom also have epilepsy (EP).
-
New Insights on STXBP1-Encephalopathy in Children
Researchers studied 19 children with STXBP1-encephalopathy, a rare genetic condition that causes severe epilepsy and developmental issues.
-
CBD May Help Reduce Seizures in Complex Epilepsy Cases
Researchers studied the effects of a highly purified form of cannabidiol (CBD), known as Epidiolex® or Epidyolex®, on people with various types of epilepsy, particularly those with developmental and epileptic encephalopathies (DEEs) and complex treatment-resistant epilepsies (TREs).
